SCHEMBL1018430

SCHEMBL1018430

COc1ccc(S(=O)(=O)c2ccc(C3CCN(C(N)=O)C3)c(C)c2)cc1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 1/20 0.47
MMP3 P08254 1/20 0.47
MMP7 P09237 1/20 0.47
MMP9 P14780 1/20 0.47
MMP13 P45452 1/20 0.47
PROKR1 Q8TCW9 4/20 0.46
CHRM2 P08172 6/20 0.45
CHRM1 P11229 5/20 0.45
CHRM3 P20309 2/20 0.45
CHRM4 P08173 1/20 0.45
PDE4B Q07343 3/20 0.43
TSHR P16473 1/20 0.43
ALDH1A1 P00352 2/20 0.43
HPGD P15428 1/20 0.43
HTR6 P50406 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1014709 0.90 MTNR1A (0.47) MMP1MMP3MMP7MMP9MMP13
SCHEMBL1014250 0.88 BTK (0.39) PROKR1CHRM2CHRM1CHRM3CHRM4
SCHEMBL1014844 0.86 STS (0.53) MMP1MMP3MMP7MMP9MMP13
SCHEMBL1015803 0.83 HTR6 (0.53) MMP13PROKR1CHRM2CHRM1CHRM3
SCHEMBL13210966 0.81 HTR6 (0.42) MMP13PROKR1CHRM2CHRM1CHRM3
SCHEMBL1012715 0.78 QDPR (0.40) PROKR1CHRM2CHRM1CHRM3CHRM4
SCHEMBL1015812 0.74 GPR119 (0.46) MMP1MMP3MMP7MMP9MMP13
SCHEMBL1012896 0.73 HTR6 (0.48) CHRM2CHRM1CHRM3CHRM4HTR6
SCHEMBL1015813 0.72 ALDH1A1 (0.47) PDE4BALDH1A1
SCHEMBL1015344 0.72 HTR6 (0.51) TSHRHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2081890-B1 ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS HOFFMANN LA ROCHE (CH) 2011-01-12 EP disclosed
US-7776910-B2 Arylsulfonyl pyrrolidines as 5-HT6 inhibitors ROCHE PALO ALTO LLC (US) 2010-08-17 US disclosed
US-7776910-B2 Arylsulfonyl pyrrolidines as 5-HT6 inhibitors ROCHE PALO ALTO LLC (US) 2010-08-17 US disclosed
US-7776910-B2 Arylsulfonyl pyrrolidines as 5-HT6 inhibitors ROCHE PALO ALTO LLC (US) 2010-08-17 US disclosed
US-20080167361-A1 Arylsulfonyl pyrrolidines as 5-HT6 inhibitors ROCHE PALO ALTO LLC 2008-07-10 US disclosed
US-20080167361-A1 Arylsulfonyl pyrrolidines as 5-HT6 inhibitors ROCHE PALO ALTO LLC 2008-07-10 US disclosed
US-20080167361-A1 Arylsulfonyl pyrrolidines as 5-HT6 inhibitors ROCHE PALO ALTO LLC 2008-07-10 US disclosed
WO-2008055847-A1 ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2008-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167361-A1 Arylsulfonyl pyrrolidines as 5-HT6 inhibitors HTR6, HTR1B, HTR1F MMP1 3738/4885MMP3 1960/4885MMP7 2407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.